Previous studies in vitro have shown an important role for intercellular adhesion molecule-i (ICAM-1) in adherence interactions of canine neutrophils with canine jugular vein endothelial cells and in cytotoxicity of canine neutrophils for adult cardiac myocytes. To evaluate the regulation of ICAM-1 in myocardial inflammation and its role in the pathogenesis of myocardial ischemia and reperfusion, a series of in vivo and ex vivo studies were performed in canine animals. Systemic administration of LPS elicited ICAM-1 mRNA in several tissues, including myocardium, which demonstrated increasing ICAM-1 staining on intercalated discs of cardiac myocytes. In ischemia and reperfusion protocols: (a) ICAM-1 mRNA was found in ischemic segments within 1 h of reperfusion and in both ischemic and normally perfused segments by 24 h of reperfusion; (b) expression of ICAM-1 was detected in cardiac myocytes in the ischemic region by 6 h of reperfusion; increased expression was seen thereafter as a function of time; (c) postischemic (but not preischemic) cardiac lymph collected at intervals from 1 to 24 h after reperfusion elicited ICAM-1 mRNA, ICAM-1 expression, and ICAM-1-dependent neutrophil adhesion in canine jugular vein endothelial cells and in cardiac myocytes with peak cytokine activity seen by 1 h; (d) extravascular localization of neutrophils was detected in ischemic areas only, and was associated with endothelium bearing high levels of ICAM-1 within 1 h of reperfusion; infiltration increased thereafter in association with increasing levels of ICAM-1 mRNA in myocardial segments and increasing levels of ICAM-1 expression on cardiac myocytes. These findings provide the first direct evidence for inflammatory regulation of ICAM-1 in ischemic and reperfused canine myocardium. They support the hypothesis that ICAM-1 participates in neutrophil-mediated myocardial damage. (J. Clin. Invest. 1993. 
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Introduction
The association of inflammation with myocardial infarction has been recognized for over 50 yr (1) . Histopathologic findings in human patients have shown that neutrophils accumulate in infarcted myocardium during the first 24 h after onset of clinical symptoms ( 1) . Numerous studies in experimental animals have shown that when ischemic myocardial tissue is reperfused with normally oxygenated blood, an inflammatory process ensues (2) . Neutrophils accumulate preferentially in ischemic myocardial segments (3) (4) (5) (6) ; this is temporally associated with the appearance of C5a and other factors chemotactic for neutrophils, which are detectable in lymph draining previously ischemic myocardium (7) . Experimental techniques designed to remove neutrophils from the circulation (3, 8-1 1 ) or to inhibit their function (2) have afforded measurable reductions in the extent of myocardial injury after ischemia and reperfusion. Such studies imply a deleterious role for neutrophil inflammatory functions in extending myocardial injury.
Several lines of evidence indicate that intercellular adhesion mechanisms are necessary for leukocyte sequestration in ischemic tissues including myocardium (12) . The important contributions of (2 integrins to this process have been shown using monoclonal antibodies administered systemically to experimental animals. Studies in canine models of cardiac ischemia/reperfusion have shown that the anti-CD 1 lb mAb 904 significantly diminished infarct size (13) (14) (15) , and the anti-CD18 mAbs MHM23 (16) , IB4 (17) , and R15.7 (18) were each capable of reducing neutrophil accumulation, during the first 6 h of reperfusion. These findings are consistent with observations of Dreyer (7, 19) , who showed that factors present in postischemic cardiac lymph stimulate the expression of CD1 lb/CD 1 8 and CDl 8-dependent adhesion of canine neutrophils. Moreover, preliminary studies in a primate model of ischemia/reperfusion injury indicate that monoclonal antibody R6.5 directed against intercellular adhesion molecule-1 (ICAM-1 ), a ligand for CD1 8 in endothelial cells and cardiac myocytes, has a protective effect (20) .
In previous in vitro studies we have shown that canine endothelial cells and cardiac myocytes express ICAM-1 in response to cytokine stimulation and that ICAM-1 functions as an adhesive molecule for neutrophils in both cell types (21) (22) (23) (24) . As shown in mAb inhibition protocols, transendothelial migration by neutrophils requires cooperative interactions of CDl lb/CD18 and CDl la/CD18 with ICAM-1 (25) (26) (27) (28) (29) . Adhesion-primed oxidative secretion by chemotactically activated canine neutrophils requires interactions of CD 1 lb/ CD1 8 with cytokine or LPS stimulated endothelial cells bearing high levels of ICAM-1 (30) (31) (32) (33) . Furthermore, oxidative cytotoxicity of canine neutrophils for cardiac myocytes also requires the interactions of ICAM-l with CD 11 /CD1 8 (21, 34) . Consistent with these findings, Youker et al. (23) have recently demonstrated the capacity of postischemic cardiac lymph to stimulate ICAM-1 in cultured endothelial cells and isolated cardiac myocytes.
The present studies extend previous in vitro work and were designed to directly evaluate the role of ICAM-1 in myocardial inflammation associated with ischemia and reperfusion. In vivo and ex vivo protocols described here provide evidence that ICAM-1 synthesis is induced in myocardium of LPS-treated dogs and that ICAM-1 is elicited in ischemic myocardium in a time-dependent manner. In addition, these studies demonstrate that factors present in postischemic cardiac lymph taken at various intervals after reperfusion are capable of inducing ICAM-1 mRNA, ICAM-1 expression, and ICAM-1-dependent neutrophil adhesion in both endothelial cells and cardiac myocytes. These findings support the hypothesis that ICAM-1 plays a role in the pathogenesis of reperfusion injury of myocardium.
Methods

Ischemia-reperfusion protocols
Healthy mongrel dogs ( 15-25 kg) of either sex were surgically instrumented as previously described (7, 21, 35, 36) . Anesthesia was induced intravenously with 10 mg/kg methohexital sodium (Brevital EL; Lilly and Co., Indianapolis, IN) and maintained with the inhalational anesthetic Isoflurane (Anaquest, Madison, WI). A midline thoracotomy provided access to the heart and mediastinum, and cannulation of the cardiac lymph duct was then performed (7) . Briefly, injection of0.05-0.2 ml of 0.5% Evans blue dye subepicardially into the posterolateral wall ofthe left ventricle allowed lymphatic vessel definition. The largest vessel was selected and cannulated at a site proximal to the cardiac lymph node and 2-5 cm from the base ofthe heart. Accessory noncardiac lymphatic vessels and tracheobronchial lymphatic connections in this region were ligated. Subsequently, a hydraulically activated occluding device and a Doppler flow probe (7) were secured around the circumflex coronary artery just proximal or just distal to the first branch. Choice oflocation depended on the proximity and anatomical arrangement of lymphatic vessels adjacent to the coronary vessels, so that subsequent dissection would not damage the lymphatic system. To prevent damage oflymphatic vessels in close proximity to the coronary vasculature, dissection ofadipose tissue adjacent to the coronary vessel at two sequential 3-4-mm sections was carefully performed, with subsequent placement of the occluding device and flow probe. In animals selected for experimental assessments of cardiac lymph, intact lymphatic vessels draining the regions of ischemic myocardium were identified by injecting Evans blue dye (0.05 ml) into the free wall ofthe left ventricle after the occluder and flow probe were in place. The appearance of Evans blue dye in the cardiac lymph cannula confirmed the patency of the lymph vessels. Indwelling cannulae, placed in the right atrium, left atrium, and femoral artery, allowed blood sampling and pressure monitoring as needed.
The animals were allowed to recover for 72 h before occlusion. Ischemia-reperfusion protocols were performed in awake animals as described (7) . Coronary artery occlusion was achieved by inflating the coronary cuffoccluder until mean flow in the coronary vessel was zero, as determined by the Doppler flow probe. At were also processed for blood flow determinations using radiolabeled microspheres as previously described (37, 38) . For comparison of the pattern of ICAM-l immunostaining, portions of myocardium were rapidly frozen from a transplanted human heart which was removed during an episode of acute rejection when a second cardiac transplant was performed.
Neutrophil isolation
Canine neutrophils were isolated from citrate anticoagulated venous blood using techniques previously described for the isolation ofhuman neutrophils (39). This yielded a preparation ofcells > 95% neutrophils with > 99% viability. These cells were suspended in Dulbecco's phosphate-buffered balanced salt solution (DPBS) and used within 4 h.
Isolation ofcardiac myocytes
Previously described procedures were used (21 ) . Briefly, healthy mongrel dogs weighing 10-15 kg were anesthetized using sodium pentobarbital. The heart was removed through the left lateral chest under sterile conditions, and immediately placed in ice-cold saline. The aorta was then cannulated using a tubing adapter suitable for the individual heart. The adapter was then connected to a peristaltic pump and retrograde perfusion was initiated using medium A Detection ofmAb binding to CJVEC For these studies, the anti-canine ICAM-l mAb (IgG,) CL18/ ID8 was used (24) . An enzyme immunoassay to detect binding of CL18/ 1D8 to monolayers of CJVEC was performed in 96-well microliter plates as previously described (25) .
Immunohistochemistry and histology
Cryostat sections 6 Mm thick were fixed in acetone and air dried. Sections were treated with 1% sodium metaperoxidate for 30 
Antibodies
The anti-CD18 mAb R15.7 (IgGl ) (21 ) and the anti-human ICAM-l mAb R6.5 (IgGl ) (40) were supplied by Dr. Robert Rothlein (Boehringer-Ingelheim Pharmaceuticals, Inc., Ridgefield, CT). The anticanine ICAM-l mAbs CL18/6 (IgGl) and CL18-1D8 (IgGl) were prepared as described elsewhere (24) .
Adhesion assays
Canine neutrophil adherence to CJVEC monolayers. Confluent monolayers of CJVEC on glass coverslips were inserted into adhesion chambers, and the adhesion ofisolated canine neutrophils was visually determined under static conditions as previously described (24, 25) . In experiments with stimulated endothelial cells, monolayers were preincubated with rTNFa (Boehringer-Ingelheim Pharmaceuticals, Inc.) or cardiac lymph for 3 h at 37°C, then rinsed by dipping coverslips five times in two changes of DPBS before inserted into adherence chambers. In experiments with mAb CL18/6 (an antibody that blocks the function of canine ICAM-1) (24), monolayers were preincubated with the mAb (10 Ig/ml) at room temperature for 5 min before rinsing in DPBS.
Canine neutrophil-myocyte adhesion. Isolated myocytes were suspended in medium A at a concentration of 50,000/ml as previously described (21) . These cells were preincubated in DPBS, TNFa, or cardiac lymph for 2-8 h at 370C before use in adhesion assays. Isolated canine neutrophils were prestimulated with 1% zymosan-activated serum (zymosan was purchased from Sigma Chemical Co., prepared as described [ 7 ] ) before use in adhesion assays. Neutrophils and myocytes were coincubated in a volume of0.4 ml at a neutrophil/ myocyte ratio of 10:1, for the last 60 min at 370C. The cells were transferred to a microscope slide for examination. For each suspension, the numbers of neutrophils adherent to each of200 myocytes was counted in a blinded fashion. In experiments with CL18 mAb, myocytes were preincubated with the mAb (40 Mg/ml) for 5 min before incubation with neutrophils.
Preparation of canine ICAM-1 cDNA. Canine spleen cDNA was amplified using PCR and degenerate oligonucleotide primer mixtures corresponding to highly conserved sequences of murine and human ICAM-l cDNA as previously described in detail (24) . Aliquots ofPCR reactions were analyzed on 1% agarose gels followed by Southern blotting and hybridization with murine or human cDNA probes for ICAM-I labeled by the random hexamer method (41 ) . A product of 740 bp was observed by ethidium staining and by hybridization with both canine -and murine PCR products. This canine PCR product was cloned into Ml 3mp 18 (42) and when sequenced, demonstrated homology to human ICAM-1 (60.9% amino acid identity) and murine ICAM-l (53% amino acid identity) within Ig domains II-V (24) .
Northern blot and slot blot analyses. RNA was isolated from cultured CJVEC, isolated canine myocytes, or myocardial tissue segments using the acid guanidinium phenol chloroform procedure (43) . For Northern blots, RNA ( 10-20 Mg) was electrophoresed in 1% agarose gels containing formaldehyde, then transferred to a nylon membrane (Gene Screen Plus; New England Nuclear, Boston, MA) by standard procedures (44) . For slot blot analyses RNA (2.5-10 Mg) was transferred to nylon membranes in a slot blot apparatus (Schleicher and Schuell, Keene, NH) under negative pressure. Membranes were hybridized in 50% formaldehyde, 10% dextran sulfate, 1% SDS, 96 mm NaCl, 0. 15 mg/ml salmon sperm DNA, and I X 106 disintegrations per minute of random hexamer 32P-labeled canine ICAM-I cDNA probe for every milliliter of hybridization solution. Filters were washed with 2 x SSC at 21°C for 5 min twice, with 2 X SSC with 1% SDS at 65°C for 30 min twice, and were then exposed to Kodak XAR film (Eastman Kodak Co., Rochester, NY).
Results
Induction ofICAM-J mRNA in canine tissues. Regulation of ICAM-l mRNA in vivo was initially studied in animals after systemic administration of LPS and in untreated control animals. After 3 h of LPS ( 1 mg/kg) administration, tissues were removed at autopsy and immediately frozen for Northern blot ( Fig. 1 a) , slot blot ( Fig. 1 b) , and immunostaining ( Fig. 1 c) analyses. Induction of ICAM-I mRNA was observed in all tissues examined, but was particularly strong in spleen, lung, kidney, and liver. In addition to a dominant hybridizing band of 2.9 kb, a lower molecular weight band of 1.9 kb was evident in some tissues, similar to that previously-demonstrated in LPS or cytokine-stimulated CJVEC in vitro (24) . As illustrated in unstimulated lung and spleen in Fig. 1 a, ICAM-l mRNA was not detected in tissues of control animals. The induction of ICAM-I mRNA by LPS was also examined in a semiquantitative fashion in slot blots. The highest levels of ICAM-1 mRNA were demonstrated in spleen, lung, and kidney, whereas lower but clearly detectable signals were evident in thymus and liver, as well as myocardium (Fig. 1 b) in the same animals confirmed the induction of ICAM-1 protein in myocardium. This was shown by intense focal staining of the CL18/ 1D8 mAb of intercalated discs of cardiac myocytes of LPS-treated animals ( Fig. 1 c) . Although the distribution and intensity of endothelial ICAM-l was similar among LPS-treated and control animals, no CL18 / 1D8 mAb staining of cardiac myocytes was evident in myocardial segments of control animals (not shown).
Induction of ICAM-J mRNA in ischemic and reperfused myocardium. To characterize the regulation of ICAM-1 mRNA in ischemic and reperfused myocardium, circumflex coronary artery occlusion and reperfusion experiments were performed. Representative experiments in two animals subjected to 1 h of coronary occlusion and 3 h of reperfusion are shown in Fig. 2 . In the experiment illustrated on the left panel (lanes 1-4) , the animal sustained a large infarct as observed visually and as confirmed by blood flow determinations. Strong signals for ICAM-I mRNA in ischemic myocardial tissue segments of this animal were observed. Signals were most evident in segments demonstrating the lowest levels of blood flow, whereas ICAM-1 mRNA was not detectable in normally perfused anterior ventricular wall segments even after 3 h of reperfusion. Contrasting findings were evident in the animal illustrated on the right panel of Fig. 2 (lanes 7-10) , which demonstrated no macroscopic evidence of infarction after the occlusion and reperfusion protocols. Subsequent myocardial blood flow determinations in this animal demonstrated only a slight reduction in perfusion despite coronary artery occlusion. In this animal, ICAM-1 mRNA was detected in normally perfused myocardial segments (Fig. 2, lanes 7 and 8) . ICAM-1 mRNA was detected in segments with diminished levels of blood flow (Fig. 2, lanes 9 and 10) , but was less intense than observed with more severe blood flow reductions. As shown, these ICAM-1 mRNA levels were comparable to those observed in myocardium of LPS-treated animals (lane 6) and to the high levels elicited by LPS (10 ng/ml, 370C, 3 h) in cultured CJVEC (lane 5).
Regulation ofICAM-J mRNA in ischemic and reperfused myocardium: relationship to time ofreperfusion and bloodflow.
To evaluate the relationship of time and induction of ICAM-I in ischemic myocardium, a series of coronary artery occlusion and reperfusion protocols were carried out. Experimental animals were subjected to 1 h ofocclusion followed by 1, 3, or 24 h of reperfusion. Large myocardial infarcts were apparent in the three animals illustrated in the top three panels of Fig. 3 a. Time-dependent induction ofICAM-I mRNA was observed in ischemic segments analyzed among each of these animals. Enhanced expression was most evident in 24 h reperfusion segments which showed tenfold increases over 1-h ischemic segments. ICAM-l mRNA was not detected in normally perfused segments of animals reperfused for 1 or .:d: Figure 2 . Induction of ICAM-l mRNA in ischemic and reperfused canine myocardium. Representative experiments are shown in two canine animals subjected to 1 h of coronary artery occlusion followed by 3 h ofreperfusion. A myocardial infarct was visually apparent in the animal shown in the left panel (lanes 1-4) , whereas no infarct was macroscopically observed in the second animal shown in the right panel (lanes 7-10). Tissue segments were isolated from infarcted posterior papillary muscle or normally perfused anterior wall myocardium of the first animal. Normally perfused myocardium from the anterior wall or segments within the circumflex artery distribution were isolated from the second animal. RNA was isolated from each segment and processed in Northern blots in a blinded fashion ( and in myocardium of LPS-treated animals (Fig. 3, a and b) . Only minimal induction of ICAM-1 mRNA was observed in myocardial segments ofan additional animal with no evidence of infarction despite 1 h of coronary artery occlusion. These relationships are graphically summarized in Fig. 4 a, where densitometric determinations of mRNA levels were computed for myocardial segments of all test animals. As shown, ICAM-l mRNA levels observed in myocardial segments were directly related to time ofreperfusion and inversely related to regional blood flow. Even normally perfused segments (left panel) demonstrated increasing levels of ICAM-l mRNA over time, but at each time interval, levels of ICAM-1 mRNA were elevated in ischemic as compared to nonischemic segments.
In addition to the findings of increasing ICAM-1 mRNA levels with time of reperfusion, an inverse quantitative relationship between ICAM-l mRNA induction and regional blood flow during the ischemic period was also observed. The results from four separate experiments in which RNA was isolated from cardiac segments after 3 h of reperfusion are shown in Fig. 4 ments, and substantially higher levels of ICAM-l mRNA in segments in which coronary blood flow was reduced by 50% or more. Generally, mRNA determinations increased as an inverse function of coronary blood flow during ischemia.
Immunostaining ofICAM-J in ischemic and control myocardial segments. The expression ofICAM-1 on vascular endothelium and cardiac myocytes was assessed in the same experimental animals using the mAb CL18/ 1D8 for immunostaining of myocardial sections. Expression of ICAM-l was observed on capillary, venous, and arterial endothelium of all myocardial segments of all experimental animals, and in cardiac tissue of normal dogs not exposed to any surgical procedures. When tissue samples were immunostained using a wide range of concentrations of mAb CL 18/ 1D8, venous and arterial endothelium generally demonstrated staining reactions at 1508 Kukielka et al. concentrations of primary antibody lower than those required to stain capillary and venular endothelium. Staining of endothelium was consistent and uniform at 20 Ag/ml but became fainter and somewhat patchy below 10 tig/ml. No differences could be detected in the intensity of endothelial ICAM-1 staining of a given vessel type when comparing control to ischemic and reperfused tissue segments, regardless ofthe concentration of primary antibody used. However, the intensity of endothelial staining for ICAM-1 was generally reduced in regions of necrosis (Fig. 5) . Expression of ICAM-1 on cardiac myocytes was also demonstrated in selected ischemia-reperfusion protocols (Fig. 5) . As with the LPS experiments in Fig. 1, expression (Fig. 5 H) .
Neutrophil accumulation after ischemia and reperfusion.
Concurrent assessments of neutrophil distribution in myocardial sections were performed in the same animals, using histologic analysis and histochemical staining for neutrophils with the anti-CD 1 8 mAb R15.7. Neither intravascular nor extravascular neutrophils were evident in sections from control (normal) animals or in normally perfused segment of canine myocardium from animals that underwent coronary occlusion. In ischemic segments, intense accumulation of neutrophils on the luminal surface of the venous endothelium and initial neutrophil transmigration was apparent after 1 h of reperfusion (Fig.   6 ). Generally, the numbers ofextravascular neutrophils in ischemic myocardium increased as a function of time of reperfusion, beginning -1 h of reperfusion, although substantially greater numbers of extravascular neutrophils were not apparent after more than 3 h of reperfusion. Infiltrating neutrophils were often concentrated in ischemic regions in the vicinity of veins which showed endothelial staining for ICAM-l when using antibody concentrations too low to stain ICAM-1 on capillary endothelium. Thus these studies indicate that early in reperfusion, neutrophil emigration occurs in ischemic myocardium concurrent with the induction of ICAM-l mRNA but before detectable increases in ICAM-1 expression on cardiac myocytes. At later time intervals where ICAM-1 staining on myocytes was observed (6-24 h of reperfusion), neutrophil emigration occurred in association with increasing levels of stainable ICAM-1 on cardiac myocytes in the ischemic areas (Fig. 6) . No neutrophils were observed in control areas which, at 24 h, showed focal ICAM-I staining on myocytes.
Stimulation ofICAM-I in CJVEC bypostischemic cardiac lymph. The capacity of cardiac lymph to stimulate ICAM-1 in CJVEC was concurrently studied in Northern blots, enzyme immunoassay, and adhesion assays as shown in Fig. 7 . Whereas recombinant TNFa (positive control) elicited ICAM-1 mRNA, surface protein, as well as total and ICAM-l-dependent adhesion for neutrophils, no stimulatory activity was seen in preischemic lymph samples. In contrast, stimulatory activity was evident in all postischemic lymph samples when tested in each assay. As shown in Fig. 8 , stimulatory activity was maximal in lymph collected during the first hour of reperfusion.
Stimulation ofICAM-I in canine cardiac myocytes bypostischemic cardiac lymph. Postischemic cardiac lymph samples taken in the first, third, and 24th hour of reperfusion were incubated with canine cardiac myocytes (Fig. 9 ) as previously described (23) . When compared to cells exposed to preischemic samples, there was a marked increase in ICAM-1 mRNA in myocytes incubated with postischemic lymph (Fig. 9) . (h) Human myocardium from a heart removed after transplantation during acute allograft rejection. ICAM-I is labeled using mAb R6.5. In addition to vascular endothelium, intercalated discs between myocytes are intensely labeled (arrows).
ulatory activity peaked in samples collected during the first hour of reperfusion. These findings are similar to the reactivity described for CVJEC in Fig. 7 . ICAM-1-dependent myocyte adhesion for neutrophils was stimulated by postischemic (but not preischemic) cardiac lymph collected during reperfusion (Fig. 9 ). This finding was further emphasized by studies shown in Fig. 1O , where neutrophil adhesion was evaluated at various time intervals (up to 8 h) after myocytes were incubated in postischemic lymph. As shown, significant ICAM-l-dependent neutrophil adhesion was demonstrated by 2 h (30 min incubation, 30 min wash, 1 h neutrophil exposure) and it continued to increase with longer incubation intervals. Similar experiments with preischemic lymph failed to induce neutrophil-myocyte adhesion (Fig. 1O) .
Discussion
These studies provide direct evidence for regulation ofICAM-l in canine myocardium in vivo after experimental ischemia and reperfusion, and they extend our previous observations in vitro implicating an important role for ICAM-l in myocardial injury. We have shown that ICAM-l mRNA is increased in isch-1510 Kukielka et al.
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- emic myocardial segments as early as 1 h after reperfusion, and is markedly elevated after longer time intervals. ICAM-1 protein was detected immunohistochemically on cardiac myocytes of ischemic segments by 6 h of reperfusion and was consistently seen after 24 h ofreperfusion. Since it was not possible to document in ischemic and reperfused segments elevated levels of endothelial ICAM-above those constitutively expressed on endothelial cells ofcontrol myocardium, the apparent basis for increased levels of ICAM-1 mRNA in reperfused myocardium could be new synthesis in cardiac myocytes. However, since postischemic cardiac lymph stimulated the expression of ICAM-1 on the surface ofcultured endothelium, it is likely that this would also occur in vivo. Our previous work clearly documents significant elevations of IL-6 activity in postischemic cardiac lymph shortly after reperfusion begins; a neutralizing antibody to IL-6 completely removes the ICAM-1-stimulating activity of postischemic cardiac lymph for cardiac myocytes (23) . Additionally, we have shown that cardiac myocytes respond to IL-6 by synthesizing and expressing ICAM-1 on the cell surface. In contrast to ischemic segments, ICAM-1 mRNA was not observed in normally perfused myocardial segments until 24 h after reperfusion. This latter finding may reflect the local release of cytokines into the systemic circulation and the subsequent induction of ICAM-I in normal tissues. In support of this idea is the fact that IL-6-like activity was previously found to persist in cardiac lymph for up to 72 h after coronary artery occlusion and reperfusion (23) .
The distribution of ICAM-1 induced on myocytes was unexpected. It apparently localized to intercalated discs ofcardiac myocytes as verified by comparisons of longitudinal and transverse tissue sections, and contrasts with both the generalized distribution of ICAM-l on isolated cardiac myocytes in vitro and the capacity of canine neutrophils to randomly bind to isolated cardiac myocytes when preincubated with cytokines or LPS (21, 24) . ICAM-1 was also observed in the intercalated discs of human myocytes in sections of myocardium after acute allograft rejection. This observation has been recently described in acutely rejected hearts by others as well (45) . Localization of ICAM-1 exclusively to the intercalated disc region remains tentative since it depends upon an immunostaining reaction highly sensitive to denaturation, and the basis for this apparent distribution in vivo is not clear. Since acute allograft rejection has previously been linked to an increase in soluble ICAM-1 (46) , it is possible that the distribution of ICAM-1 is influenced by cleavage of the molecule. A recent paper describes such cleavage of ICAM-1 associated with inflammatory mediators (47).
Postischemic cardiac lymph, in contrast to lymph collected before coronary occlusion, stimulated both endothelial cells and isolated myocytes in vitro to express ICAM- 1 have not been completely defined. We have previously shown that IL-6, IL-lI, TNFa, and endotoxin will stimulate ICAM-l expression in isolated canine cardiac myocytes (23, 24) and that TNFa and endotoxin will stimulate ICAM-1 expression in CJVEC (24) . There is now evidence for the presence of IL-6 in postischemic cardiac lymph (23) , but since there is no published evidence that IL-6 will stimulate ICAM-1 production by endothelial cells, it is likely that other cytokines are present in cardiac lymph as well. Factors in lymph stimulating ICAM-1 expression also appear to be distinct from those shown to induce other adhesion determinants in ischemic myocardium. For example, Manning et al. have shown that stimulatory activity for P-selectin mRNA in postischemic cardiac lymph is maximal after 24 h of reperfusion (49) . This finding is temporally inconsistent with the present studies of ICAM-1 mRNA. Thus, it appears that heterogeneous inflammatory mediators are operative as a consequence of myocardial ischemia, and that mechanisms involving differential regulation of several adhesion pathways may contribute to subsequent inflammatory events.
Based on our previous observations in vitro, it is reasonable to propose that ICAM-1 facilitates both the emigration of neutrophils in reperfused myocardium and their adherence-dependent cytotoxic behavior (21, 23, 24, 50) . Constitutive levels of ICAM-1 on endothelial cells appear to be sufficient to support CDl 8-dependent transendothelial migration of neutrophils in response to chemotactic stimuli (27) . Since we were unable to show increased ICAM-1 expression on endothelial cells in the ischemic and reperfused cardiac segments, and since Dreyer et al. (7, 19) have clear evidence for chemotactic activity in the extracellular fluid of ischemic and reperfused myocardium, it is possible that the constitutive ICAM-1 would play such a role in vivo. In contrast, the cytotoxic activity of neutrophils for cardiac myocytes in vitro is dependent on newly synthesized ICAM-1 expressed on the surface ofthe myocyte after cytokine stimulation (34, 5 1 ) and chemotactic upregulation of CD 1 ib/ CD1 8 on neutrophils (52) . A CD1 lb/CD18-dependent mechanism apparently augments the neutrophil's oxidative burst after chemotactic stimulation (21, 30 (6, 19) supports this hypothesis. It is likely that some myocyte ICAM-1 actually may be expressed before the 6 h period required for immunostaining based on data in vitro in Fig. 10 . However, a series model with a neutrophil transmigration phase preceding the expression of parenchymal ICAM-1 seems reasonable.
The use of anti-ICAM-1 mAb in experimental models of myocardial ischemia and reperfusion has resulted in reduced tissue damage, then further supporting a deleterious role for ICAM-l in this process, at least within the initial 5 h after coronary artery occlusion. The R6.5 mAb (1 mg/kg) was shown to attenuate myocardial necrosis in rabbits when given intravenously 15 min before 1 h ofocclusion followed by 5 h of reperfusion (53) . Preliminary studies using R6.5 mAb also demonstrated protection against myocardial necrosis in primates when provided 30 min before 90 min of coronary artery occlusion and 4 h of reperfusion (20) . Several studies have shown protective efficacy of anti CD1 8 or CDl lb monoclonal antibodies in canine (13) (14) (15) 18) , rabbit (53, 54) , and primate (20) models of myocardial ischemia and reperfusion. Since ICAM-l is a natural ligand for CD1 la/CD 18 and CD1 lb/ CD1 8 subunits, these studies indirectly support the participation of ICAM-1 in myocardial injury. However, CD1 8-dependent neutrophil sequestration and certain CDl 8-dependent functions (e.g., homotypic aggregation) contributing to inflammatory injury may involve ICAM-1 independent mechanisms (Smith, C. W., personal communication). Recent studies by Dreyer et al. ( 18) demonstrate increased CD I 8-dependent sequestration of radiolabeled canine neutrophils in ischemic canine myocardium limited to the initial 4 h of reperfusion. These findings are consistent with the present findings showing constitutive levels of ICAM-1 on endothelial cells, and upregulation of ICAM-1 on myocytes at later time intervals. As chemotactic activity in ischemic lymph evolves and wanes during the initial 4 h of reperfusion in our experimental model (7, 18, 19) , the pathogenic behavior of neutrophils may involve the upregulation and adhesive interactions of CDl lb/CD 18 with its ligand(s) on neutrophils and endothelial cells, and with newly expressed ICAM-1 on myocytes (24, 34) .
Although intense margination and initial transmigration of neutrophils were seen at 1 h after reperfusion, prominent interstitial infiltrates of neutrophils were seen by 3 h of reperfusion of ischemic myocardial segments, comparable to those seen at later time intervals. This correlates very well with our previous work demonstrating leukotactic activity in the cardiac lymph (7, 19) and radiolabeled neutrophil influx ( 18) occurring principally in the first 3-4 h of reperfusion.
Previous reports have described an acute inflammatory reaction during the early period of myocardial reperfusion and suggest that inflammatory infiltration is seen only much later when ischemic tissue is not reperfused (55) (56) (57) (58) (59) . Pathologic changes described in human autopsy material are consistent with the experimental findings in animals subjected to permanent ischemia without reperfusion ( 1) . In the present studies emigrating neutrophils were consistently regionally associated with veins demonstrating strong ICAM-1 staining, further suggesting a relationship ofthe constitutive endothelial ICAM-1 to neutrophil transmigration.
Previous investigations in experimental animals and biopsies of human tissues document the upregulation of ICAM-1 in vivo on cells other than endothelium. In response to various inflammatory mediators, ICAM-1 can be induced not only on endothelial cells, but on a broad spectrum ofmesenchymal and epithelial cell types (60) (61) (62) (63) . The kinetics of induction of ICAM-1 on cardiac myocytes as shown here are similar to those observed by Vejlsguard et al. (62) on keratinocytes of human skin after allergic contact dermatitis testing, who demonstrated induction of ICAM-1 on human keratinocytes as early as 4 h after application of contact patches. By 48 h after contact, all specimens expressed ICAM-1 on keratinocytes concurrent with the appearance ofheavy mononuclear cell dermal infiltrates and maximal clinical signs of dermatitis. Related studies in a murine model of contact dermatitis showed focal ICAM-1 expression on keratinocytes 24 h after dinitrofluorobenzene challenge and high levels of ICAM-l on all keratino-cytes 72 h after challenge (64). Adams et al. reported marked induction of ICAM-1 on bile ducts, endothelium and perivenular hepatocytes of liver allografts in patients with acute or chronic rejection (63) ; in this setting, ICAM-1 may serve to initiate the inflammatory response of rejection and/or to determine the cellular targets for CD I 8-dependent immune damage by infiltrating lymphocytes and neutrophils (65) . Induction of ICAM-1 on vascular or tubular cells may serve a similar role in renal allograft rejection (66, 67) and increased levels of ICAM-1 on lung epithelial cells elicited by Ascaris antigen in sensitized primates may facilitate the pathogenic effects of eosinophils (61 ) .
The present study strengthens our previous suggestions regarding a potential role for ICAM-1 in inflammatory injury of the myocardium. It confirms our hypothesis that ICAM-1 is induced in ischemic myocardium. These studies indicate that the expression of ICAM-1 on tissue or parenchymal cells is possibly an important pathogenic mechanism facilitating the cytotoxic potential of neutrophils and other leukocytes.
